Netherlands-based biotechnology company SkylineDx announced on Sunday new data from its MERLIN_001 trial, a US study evaluating a melanoma genomic assay.

Initial results were presented at the Society for Melanoma Research Annual Meeting in New Orleans. Conducted at nine US academic sites, the study was led by three principal investigators from Moffitt Cancer Center, Mayo Clinic, and UofL Health.

The trial validated the predictive power of SkylineDx's CP-GEP Merlin test in identifying sentinel lymph node biopsy (SLNB) status in high-risk melanoma patients. Results showed the Merlin test could classify 37% of patients as Low Risk, with a negative predictive value of 92.9%. This stratification helps clinicians better determine which patients may safely avoid SLNB, reducing unnecessary procedures. The test's ability to guide treatment decisions aligns with current NCCN guidelines for melanoma management.